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To identify knowledgegaps regardingnew-onset agitationand impulsivity prior toonset
of cognitive impairment or dementia the International Society to Advance Alzheimer’s
Research andTreatmentNeuropsychiatric Syndromes (NPS) Professional InterestArea
conducted a scoping review. Extending a series of reviews exploring the pre-dementia
risk syndrome Mild Behavioral Impairment (MBI), we focused on late-onset agitation
and impulsivity (the MBI impulse dyscontrol domain) and risk of incident cognitive
decline and dementia. This scoping review of agitation and impulsivity pre-dementia
syndromes summarizes the current biomedical literature in terms of epidemiology,
diagnosis andmeasurement, neurobiology, neuroimaging, biomarkers, course and prog-
nosis, treatment, and ongoing clinical trials. Validations for pre-dementia scales such
as the MBI Checklist, and incorporation into longitudinal and intervention trials, are
needed to better understand impulse dyscontrol as a risk factor for mild cognitive
impairment and dementia.
K EYWORD S
agitation, disinhibition, impulse dyscontrol, impulsivity, MBI, mild behavioral impairment, pre-
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1 INTRODUCTION
Neuropsychiatric symptoms (NPS) arenon-cognitivebehavioral or psy-
chiatric symptoms in dementia or pre-dementia syndromes and are
also sometimes referred to as behavioral and psychological symptoms
of dementia (BPSD). Clinicians have been aware of NPS as a manifes-
tation of dementia since the time of Alois Alzheimer and his descrip-
tion of the first patient with Alzheimer’s disease (AD), who besides
showing rapid cognitive decline, displayed NPS in the form of para-
noia, agitation, and hallucinations.1 The Cardiovascular Health Study
found that 75% of dementia patients experienced a neuropsychiatric
symptom in the month prior to evaluation,2 while the Cache County
Study found the 5-year period prevalence of NPS to be 97% in patients
with dementia.3 NPS are associatedwithworse disease prognosis4 and
earlier death.5 NPS also presents in mild cognitive impairment (MCI),
although less frequently than in dementia, withNPS inMCI prevalence
estimates ranging from 31% to 60%.6,7 These NPS in MCI are more
prevalent in the clinical versus community settings, underscoring their
clinical significance.8
For decades, cognitive symptoms were given priority in the diagno-
sis of dementia, although inmany cases NPS preceded or accompanied
cognitive symptoms. More recently, an AD variant has been described
inwhich a dysexecutive or behavioral syndromemanifests prior to cog-
nitive symptoms.9 Similarly, behavioral symptoms frequently present
as the first clinical signs of frontotemporal dementia (FTD).10 Often,
patients with this type of neuropsychiatric presentation will seek out
psychiatric consultation and receive a diagnosis of a primary psychi-
atric disorder, without consideration of a potential prodromal or pre-
dementia syndrome.11 There is evidence and increasing consensus
that NPS can be an early manifestation of dementia in cognitively
asymptomatic subjects or in those with MCI.12,13 Studies in the gen-
eral population6,14 and in clinical cohorts support the idea that NPS in
MCI increase the risk of incipient dementia, with an annual progres-
sion rate of 25% inMCIwithNPS15,16 versus an annual general conver-
sion of 10%-15%.17 Likewise, the presence of NPS in cognitively nor-
mal older adults also increases the progression to dementia, as indi-
cated by several studies, such as the Alzheimer’s Disease Cooperative
Study,18 the Psychiatric Registry and Danish Physician,19 the Mayo
Clinic Study of Aging,20 theMedical Research Council Cognitive Func-
tion and Aging Study,21 and the National Alzheimer’s Coordinating
Center (NACC).22–24 Recently, an analysis of 1988 NACC participants
demonstrated that NPS precede cognitive symptoms 59% of the time
across dementias, and even in AD, 30% of participants developed neu-
ropsychiatric symptoms in advance of cognitive symptoms.25 These
data emphasize the importance of later-life onset of NPS in dementia
risk assessment.
The Alzheimer’s Association International Society to Advance
Alzheimer’s Research (ISTAART) NPS professional interest area (PIA),
identified in 2012 the need to set an agreed upon construct and defini-
tion forNPS pre-dementia syndromes. Building on the prior definitions
of a pre-dementia risk state by Taragano et al.12,13 and frontotemporal-
MCI bydeMendonca et al.,10 the ISTAARTNPS-PIA formally described
mild behavioral impairment (MBI) as the emergence of sustained and
impactful NPS occurring after the age of 50, which are not captured
by traditional psychiatric nosology, persist for at least 6 months, and
manifest in advance of or in concert with MCI.26,27 Operationalized,
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the ISTAART MBI research definition required change in at least one
of five areas of personality and behavior: (a) decreased motivation (eg,
apathy, aspontaneity, indifference); (b) affective dysregulation (eg, anx-
iety, dysphoria, changeability, euphoria, irritability); (c) impulse dyscon-
trol (eg, agitation, disinhibition, gambling, obsessiveness, behavioral
perseveration, stimulus bind); (d) social inappropriateness (eg, lack of
empathy, loss of insight, loss of social graces or tact, rigidity, exagger-
ation of previous personality traits); and (e) abnormal perception or
thought content (eg, delusions, hallucinations).26 Thus,MBI represents
the neurobehavioral axis of pre-dementia risk states, and complements
the traditional neurocognitive axis represented by subjective cognitive
decline (SCD) andMCI.
This scoping review follows the definition proposed by Colquhoun
et al. in 2014, where a, “Scoping review is a form of knowledge syn-
thesis that addresses an exploratory research question aimed at mapping
key concepts, types of evidence, and gaps in research related to a defined
area or field by systematically searching, selecting and synthesizing existing
knowledge.28” Scoping reviews describing the evidence for neuropsy-
chiatric symptom sets as predictors of dementia have been completed
for the other MBI domains of decreased drive/motivation,29 affec-
tive/emotional dysregulation,30 social inappropriateness,31 and abnor-
mal perception and thought content.32 The purpose of this scoping
review is to describe the current evidence and identify gaps in the
biomedical literature for the epidemiology, neurobiology, neuroimag-
ing, biomarkers for blood and cerebrospinal fluid (CSF), prognosis, and
completed and ongoing trials for treatment of later-life impulsivity and
agitation as predictors of dementia. As such, there are different sec-
tions specific to each of the previously named categories. It is impor-
tant to understand the prevalence of agitation and impulsivity in pre-
dementia syndromes as there is a potential opportunity for early inter-
vention and higher impact in this early stage of illness. The number of
studies in the completed search thatmet full inclusion criteriawere too
numerous (n = 136) to include every study in this review paper. Thus,
the authors summarized themost pertinent and included asmany stud-
ies as was reasonably possible.
2 METHODOLOGY
A comprehensive search of the biomedical literature was performed
by a medical librarian using the following databases: Ovid MEDLINE,
PubMed (for non-MEDLINE records), Embase, Cumulative Index to
Nursing and Allied Health Literature (CINAHL), and PsycInfo.
Searches for Ovid MEDLINE, PubMed, Embase, CINAHL, and
PsycInfo were initially performed in January and February 2018,
and then updated on April 26, 2019. The search strategies for each
database are reported in Supplement 1.
Abstracts and full-text articles were screened by a team of
reviewers—S.G., S.H., Z.I., M.M., and D.B. A third reviewer acted as a tie
breaker when the initial two reviewers were unable to come to agree-
ment. Abstract screening was conducted in Covidence, an online soft-
ware that allows reviewers to access and resolve inclusion/exclusion
conflicts, as well as track the progress of other reviewers, thus improv-
RESEARCH INCONTEXT
1. Scoping Review: MEDLINE, PubMed, Embase, CINAHL,
and PsycInfo were searched for impulse dyscontrol and
agitation keywords in pre-dementia and dementia popu-
lations. A total of 4540 abstracts were screened in dupli-
cate, 295 selected for full-text review and 136 included in
the final manuscript.
2. Interpretation: The research in agitation is more robust
than that for impulsivity, in part due to a poorly estab-
lished definition of impulsivity. Nonetheless, early evi-
dence suggests that later life onset of ImpulseDyscontrol,
a domain in the pre-dementia risk syndromeMild Behav-
ioral Impairment, is important to explore in determining
risk of dementia.
3. Future Directions: We describe the ongoing and future
research agenda for study of Impulse Dyscontrol for
dementia prognostication and early detection. This
agenda includes improving measurement, including fluid
and imaging biomarkers in cross-sectional and longitudi-
nal trials, and assessing the role of different interventions
in mitigating symptoms and decreasing risk of incident
cognitive decline and dementia.
ing the efficiency of conducting a review. Duplicates were removed
using EndNote.
Inclusion criteria were studies focused on pre-dementia or MCI,
and NPS or BPSD. Other dementias such as behavioral variant fron-
totemporal dementia (bvFTD), vascular dementia (VasD), dementia
with Lewybodies (DLB) andParkinson disease dementiawere included
if there was a focus on NPS in individuals with pre-dementia. Studies
with an elderly population with cognitive impairment and NPS were
also included.
Exclusion criteria were other disease focus such as subjects with
Down syndrome, Huntington disease, dementia due to human immun-
odeficiency virus, or traumatic brain injury (TBI). Studies without pre-
dementia, MCI, NPS, or BPSD were excluded. In addition, animal and
non-English studies were excluded.
A total of 5329 citations/abstracts were retrieved through searches
of these databases. From this total, 1326 duplicates were removed,
resulting in a final set of 4540 citations/abstracts for review. Follow-
ing screening, 295 articleswere selected for full-text review. From that
subset, 136 full-text articles were included in the review. Studies that
included a minimum of three subjects and met inclusion criteria were
then reviewed by the authors for clinical relevance and research qual-
ity. Publications that included overlapping patient samples were culled
and the most salient publication was included. In addition, 194 articles
were identified independently by authors and included in the scoping
review (See Figure 1).33
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3 EPIDEMIOLOGY
NPS are common in patients with MCI, occurring in 35%-75%
of individuals.34 The International Psychogeriatric Association (IPA)
2015 Consensus Provisional Definition of Agitation in Cognitive Dis-
orders defines agitation broadly as: “(1) occurring in patients with a cog-
nitive impairment or dementia syndrome; (2) exhibiting behavior consis-
tent with emotional distress; (3) manifesting excessive motor activity, verbal
aggression, or physical aggression; and (4) evidencing behaviors that cause
excess disability and are not solely attributable to another disorder (psy-
chiatric, medical, or substance-related).35” Agitation is one of the most
commonNPS reported inMCI patients; however, prevalence estimates
vary drastically from 5% to 25% in population-based studies,34 and 4%
to 45% in hospital-based studies.36 These wide ranges are likely due
to differences in patient setting (population-based vs clinical trial set-
ting), MCI diagnostic criteria used (amnestic vs non-amnestic), differ-
ences in scales used to assess agitation, and the exclusion of patients
with depressive symptoms in some studies (InDDEX trial).37
Of interest, in a longitudinal population-based study by Copeland
et al., agitation was more prevalent in patients who had a CDR score
of 0.5, and progressed to AD (36% at baseline) than in patients who
remained stable at a CDR score of 0.5 (18% at baseline), compared to
patients who had a CDR score of 0 at baseline and follow-up (6%).38
In the Mayo Clinic Study of Aging, in 2008, Geda et al. reported
that in 1969 non-dementia patients,39 the prevalence of agitation and
irritability was greater in patients with amnestic compared to non-
amnestic MCI, and that Neuropsychiatric Inventory (NPI)–measured
disinhibition, which some have categorized as an impulsive behavior,
wasmore prevalent in patientswith non-amnestic compared to amnes-
tic MCI. These findings are corroborated by a large cross-sectional
cohort study with 512 patients diagnosed with MCI, which found that
aggressive symptoms were more prevalent in patients with single-
domain amnestic MCI, compared to patients with single-domain non-
amnestic and multi-domain MCI. Disinhibition was also found to be
more prevalent in patients with single-domain non-amnestic MCI as
compared to single-domain amnestic and multi-domain MCI.40 On the
contrary, in 2011, Rosenberg et al. found that the prevalence of NPS
such as agitation and disinhibition did not differ between patients with
amnestic compared to non-amnestic MCI. However, the authors also
reported that in patients with MCI and executive dysfunction, NPS
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were more frequent including agitation, irritability, and disinhibition,
alongwith depression, anxiety, apathy appetite, and sleep disturbances
than inMCI patients without executive dysfunction.41
Compared to agitation, impulsivity has not been well studied in
patients with dementia, likely due to imprecise characterization of
impulsivity, and few scales available to assess this NPS in this popu-
lation group. As such, the data available on the prevalence of impul-
sivity in pre-dementia states are very limited. However, a number of
recent studies have worked to characterize the prevalence of impulse
dyscontrol in pre-dementia populations. Creese et al., received com-
pletedMBIChecklist27 from10,952 individuals over the age of 50with
no diagnosis of dementia, and found an overall prevalence of behav-
ioral disturbances in 47.5% of respondents and prevalence of impulse
dyscontrol in 31% of respondents.42
Data published on the PArkinson’s disease Cognitive impairment
Study, a large, cross-sectional, hospital-based study of two movement
disorder centers in southern Italy, found a cumulative prevalence of
MBI of 84.1% in 429 non-demented subjects with Parkinson disease
(PD).43 Prevalence of impulse dyscontrol in the same cohort differed
according to disease progression, with 35.5% among those with ≤1
year of PDversus 47.6%of thosewithPD>1year (P= .021).43 Another
study of 326 subjects with PD found the prevalence of impulse con-
trol disorders (ICDs) in PD patients with normal cognition, MCI, and
dementia to be 55%, 50%, and 42% respectively.44
In a large retrospective study of 3,456 patients with MCI from
the NACC data set, Apostolova et al. (2014) used factor analysis to
group NPI items into four different factor groups: affective behav-
iors (depression, apathy and anxiety); distress/tension behaviors (irri-
tability and agitation); impulse control behaviors (disinhibition, elation
and abberant motor behavior); and psychotic behaviors (delusions and
hallucinations).45 Impulse control behaviors included disinhibition, ela-
tion, and aberrant motor behaviors. The author reported that male
gender was significantly associated with all NPS factors (including dis-
tress/tension and impulse control). In addition, younger agewas associ-
ated with an increased prevalence of distress/tension, impulse control,
and psychotic behaviors, and lower education was significantly associ-
ated with the presence of distress/tension behaviors only.45
Posttraumatic stress disorder (PTSD) has been identified as a risk
factor for development of dementia in both female46 andmale combat
veteran populations.47–49 At this time, studies assessing whether the
combinedpresence of agitation andPTSDor impulsivity andPTSDpre-
dict dementia havenot been completed. The two studies that examined
whether veterans with PTSD and dementia had higher rates of agita-
tion as compared with patients with dementia without PTSD showed
no significant differences in agitation rates between the two different
populations.50,51
Late life depression has also been well described as a risk factor
for development of dementia,52 but recent evidence has also explored
depression as a prodrome.53 Several large longitudinal cohort stud-
ies have suggested that assessment of depression in the context of
the overall natural history of symptoms is essential to distinguishing
between depression as risk factor or prodrome. These studies demon-
strate that the later in life the onset of psychiatric symptomatology,
the more likely these symptoms represent the early stages of a neu-
rodegenerative process that precede dementia by 5-11 years.30 This
distinction, incorporating age of onset and past history of symptoms, is
at the crux of appreciating the relationship between neuropsychiatric
symptomatology and risk of dementia and is consent with the overall
concept of MBI. This logic applies to new-onset impulsivity and agita-
tion as well.
Impulsive behaviors are considered to be a hallmark of bvFTD.54
However, findings from a retrospective case study of bvFTD patients
suggest that impulsive behaviors may be detected in the pre-dementia
stages as well.10 The authors also proposed frontotemporal-MCI cri-
teria, which are available for further validation on larger samples and
longitudinal follow-up.10
In a 1-year longitudinal observational study with 76 elderly individ-
uals 60 years of age and older, Tamam et al. investigated the preva-
lence of ICDs using the self-administered Minnesota Impulse Disor-
ders Interview(MIDI), and impulsivity using the Baratt Impulsiveness
Scale Version 11 (BIS-11). The authors reported that ≈22% of the par-
ticipants had at least one ICD.55 The most common ICD was inter-
mittent explosive disorder (15.8%), followed by pathological gambling
(9.2%). Although these participants were followed for only 1 year, the
results of this study suggests that approximately one in five patients
over the age of 60 have at least one ICD, and additional longitudinal
research is required to assess ICDs as a potential risk factor for cog-
nitive decline and dementia.55 Older adults with normal cognition can
also experience impulse control or disinhibition, albeit less frequently
as compared to those with MCI or dementia. Impulsivity, as assessed
by theNPIDisinhibition item, seems to be infrequent in non-demented
elderly individuals in community and clinical settings.20,34,36,56,57
The highlighted literature demonstrates that the prevalence esti-
mates of agitation and impulsivity vary drastically between studies.
In total, these findings support that agitation is a prevalent NPS in
patients at risk for developing dementia, and that impulsive behav-
iors may also present as an individual NPS, or co-occur with agitation.
It should be noted that almost all of the described studies are cross-
sectional in nature and do not get at the important issues of agitation
and impulsivity as a risk factor for cognitive or functional decline and
incidentMCI.
4 DIAGNOSIS AND MEASUREMENT
Avalid detection anddiagnosis ofNPSdepends heavily on the choice of
a goodmeasure. A variety of scales exist, with differences in symptoms
of interest (overall behavioral changes vs specific constructs), assessor
(patient, caregiver, or clinician), time frame (eg, 1 week vs 6 months),
and symptom dimensions assessed (frequency, severity, or distress).
The scales described below—the Cohen-Mansfield Agitation Inven-
tory (CMAI),58 The Brief Agitation Rating Scale (BARS),59 the Overt
Agitation Severity Scale (OASS),60 the Agitated Behavior in Demen-
tia Scale (ABID),61 and the Pittsburgh Agitation Scale (PAS)62 and
variations of the NPI63,64—were designed and validated for demen-
tia populations. The number of agitated behaviors or characteristics
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of agitation described vary depending on the scale: CMAI, 29; BARS,
10; OASS, 47; ABID, 16; PAS, 4; and the NPI, 8 (NPI-Q, 1 and NPI-
C, 21; agitation & aggression). Many items included in these scales
describe behavior relevant to patients with mild to severe demen-
tia and may not apply to community-dwelling older adults without
dementia. None of these scales were designed for pre-dementia pop-
ulations. However, the CMAI, NPI, NPI-Q, and NPI-C were studied in
MCI populations.65–68
The CMAI was developed to systematically assess agitation in peo-
plewithdementia, often in nursinghomes. It consists of 29descriptions
of agitatedbehaviors, each ratedon a7-point scale basedon frequency,
ranging from never manifesting the behavior (score of 1) to manifest-
ing the behavior several times an hour (score of 7), with a possible
score range of 29-203.58 Four different agitation factor sub-scores
on the CMAI have been identified and are used as secondary out-
comemeasures: (1) aggressive physical behavior (hitting, kicking, push-
ing, scratching, tearing things, and cursing); (2) nonaggressive physi-
cal behavior (pacing, inappropriate robingor disrobing, repetitious sen-
tences or questions, trying to get to a different place, general restless-
ness, handling things inappropriately and repetitious mannerisms); (3)
verbally aggressive behavior (complaining, constant request for atten-
tion), and (4) verbally nonaggressive behavior (negativism, repetitious
sentences or questions and complaining).
Despite the dementia-centric language, the CMAI was adminis-
tered to an MCI population in a recent Belgian study, which suggested
a different pattern of agitated behaviors. Compared to agitated AD
patients, agitated MCI patients presented with significantly less (ver-
bally and physically) aggressive behavior (1% vs 19%) and physically
non-aggressive behavior (41% vs 80%), but more verbally agitated
behavior (83% vs 76%).69 However, the CMAI was designed and vali-
dated in those with more severe disease. A slightly different symptom
manifestation early in the course of the disease may be one of the rea-
sons for contrasting findings in NPS prevalence when general scales
are used, suggesting that early symptom manifestations may require
more sensitive screening questions, or those designed specifically for
pre-dementia populations.
Of general psychopathology scales, the NPI is the most commonly
used both in research and clinical practice.63 The NPI begins with
a screening question for each of the 12 neuropsychiatric domains,
answered by a close informant in an interview. In case of a positive
answer, a subset of questions specifies the depth and complexity of
the domain. The scale provides information on frequency, severity, and
caregiver distress of the specific domain within the past month. How-
ever, in 2005, it was found that only 28.6% of large European mem-
ory clinics used the NPI routinely to assess patients with cognitive
impairment.70
A short version of the NPI, the Neuropsychiatric Inventory—
Questionnaire (NPI-Q), includes screening questions, symptom sever-
ity, andcaregiverdistress in the instrument. Itwasdesigned to facilitate
the screening of NPS in clinical practice.71 Due to its time-efficiency
the NPI-Q has been incorporated into research and into cognitive
batteries, such as the Uniform Data Set (UDS).72 However, for the
agitation/aggression domain, a screening question “Does the patient
have periods when he/she refuses to cooperate or won’t let people help
him/her? Is he/she hard to handle?” may not cover the variety of agi-
tated behaviors present in the pre-dementia population, thus leading
to under-reporting. An NPI-Q agitation/aggression subscale, originally
developed in nursing home residents may address this issue.73 It con-
sists of four NPI-Q items that emerged as a symptom cluster in sev-
eral factor analyses including agitation/aggression, irritability, aberrant
motor behavior, and disinhibition. Although requiring further valida-
tion, according to a comparative study of NACC and ADNI cohorts,
the scale appears to be a promising index of agitation in patients with
MCI.66
Another potentially useful subscale for future studies may be
the Agitation subscale from the Neuropsychiatric Inventory—
Clinician (NPI-C), a clinician rated version of the NPI.64 The Agi-
tation/Aggression item from the original NPI has been separated
into NPI-C Agitation and NPI-C Aggression, with an option of both
domains to be used as standalone measures.64 The authors report a
significantly stronger correlation of NPI-C Agitation domain with the
CMAI compared to the original NPI Agitation/Aggression, suggesting
that the revised domain is amore comprehensivemeasure of agitation.
The domain separation also appears to be clinically relevant, as in one
study using semi-structured interviews, agitation was found to be
more prevalent than aggression in MCI.67 In addition, significant dif-
ferences were reported in agitation prevalence between patients with
MCI and mild AD, but this did not apply to aggression.67 Incorporating
the clinician´s judgment is also considered valuable when investigating
the pre-dementia population, mainly because of differences found
between agitation severities rated by clinicians versus caregivers.68
Future studies are needed to confirm the diagnostic utility of NPI-C in
pre-dementia stages. One disadvantage of the NPI-C compared to NPI
or NPI-Q is the longer administration time, particularly because the
instrument is designed so that all questions are asked and there is no
screening question or any “skip-out” of subsequent questions for any
NPI-C domain, as there is in the NPI.
The Barratt Impulsiveness Scale (BIS-11) and Behavioral Inhibition
and Behavioral Activation Scales (BIS/BAS) are self-report question-
naires that have been commonly used in psychiatry. The BIS-11 is
a 30-item scale assessing three dimensions: attentional, motor, and
non-planning impulsiveness.74,75 The BIS/BAS is a self-report mea-
sure including four dimensions: behavioral inhibition, reward respon-
siveness, drive, and fun seeking.76 A recent functional magnetic reso-
nance imaging (fMRI) study on individuals with SCD using these scales
reported that although SCD participants made fewer future-oriented
decisions compared to healthy controls on a behavioral task, no signifi-
cant differences were found between the groups on both scales except
a slight, but significantly lower scoreon theBIS/BASdrivedimension.77
In contrast, a large Australian study of non-demented, community-
dwelling 60- to 64-year-old adults found significant differences on the
BIS/BAS behavioral inhibition subscale between those with memory
complaints and those without.78
Despite these findings, various issues need to be acknowledged
when considering using the previously described questionnaires in
the pre-dementia population. The questionnaires measure long-term
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patterns without relation to a time frame. Therefore, they may not be
sensitive to possible late-life behavioral change. In addition, self-report
questionnaires may produce slightly different results compared to
informant-ratedmeasures. Regarding the latter, the BIS scale has been
recently modified into an informant-rated scale and has become part
of the NACC database UDS-FTLD module.79 Although more research
is needed in this area, it does seem that new or revised scales may be
required for detecting subtle changes in impulsive behavior.
Recently, a new time-efficient, informant-based questionnaire, the
Mild Behavioral Impairment—Checklist (MBI-C), has been introduced,
with items designed specifically to detect subtle changes in persons
with nomore thanMCI.27 TheMBI-C stipulates later-life emergence of
symptoms and a 6-month period of symptom persistence as opposed
to 1- to 4-week time frame of the other NPS scales, which helps to
exclude various transient reactive states (eg, medication, sleep depri-
vation, etc), decreasing false positives. Of the five MBI domains, the
impulse dyscontrol domain provides assessment of agitation, aggres-
sion, and impulsivity symptoms. The MBI-C is the first measure devel-
oped specifically for the pre-dementia population, and the ongoing val-
idation studies42,80–85 will determine its diagnostic utility. Early valida-
tion results have determined cut-points for MBI diagnosis in SCD85,86
and MCI, and have demonstrated a five-factor model for the MBI-C
with an intact impulse control/agitation domain,42,87 test-retest relia-
bility, construct validity, and discriminative validity from the NPI.84,85
Furthermore, a 1-year longitudinal study has shown the emergence of
MBI with cognitive decline in cognitively normal older adults.42
Overall, the evidence suggests that there are many scales used to
assess NPS without validation in the pre-dementia population, a trend
that has been observed previously across European centers.70 As such,
future investigations are encouraged to use validated scales of NPS
specific to the pre-dementia population. However, different defini-
tions of agitation have impeded systematic study of this syndrome. In
response to this clinical and researchgap, the IPAdeveloped criteria for
agitation in dementia in which symptoms are divided into the domains
of excessive motor activity, verbal aggression, and physical aggression
domains.35 Of note, the criteria extend back to theMCI phase, but not
to older adults with normal cognition, and have yet to be operational-
ized into a validated rating scale.
5 NEUROBIOLOGY OF AGITATION AND
IMPULSIVITY
Clinicopathological studies suggest that the dorsolateral prefrontal,
orbitofrontal, and anterior cingulate cortices are important for emo-
tional regulation and processing, through their interactions with the
sensory cortex, amygdala, and the medial temporal regions.88,89 Dam-
age to one or more of these regions results in emotional dysregulation,
including disinhibition, aggression, and agitation.88 In individuals with
AD, the severity of agitation correlates with the extent of neurofibril-
lary tangle pathology in the bilateral orbitofrontal cortices and ante-
rior cingulate regions,89 andwith the degree of temporal limbic cortical
hypoperfusion on 18F-fluorodeoxy-glucose positron emission tomog-
raphy (PET).90 Consistent with these findings, studies using the tau
tracer 18F-THK5351 in cognitively impaired individuals have shown
associations between irritability and tau burden in the bilateral mesial
frontal, bilateral dorsolateral prefrontal, right temporal pole, and right
superior temporal cortices.91 In preclinical AD, higher NPI scores, par-
ticularly measures of irritability/lability and sleep/nighttime behavior,
predicted subsequent hypometabolism in the posterior cingulate cor-
tex over 2 years,92,93 which supports the notion that such behavioral
changes may be associated with incipient cognitive decline. On the
other hand, no clear associations have beenobserved between amyloid
burden on PET using Pittsburgh Compound B (PET-PIB) and neurobe-
havioral changes in AD,94 and studies have been inconclusive regard-
ing relationships between the apolipoprotein E gene (APOE) 𝜀4 carriers
and agitation.95,96
Results of studies investigating associations between regional cor-
tical volumes and agitation measures in AD using voxel-based mor-
phometric MRI have been mixed. Some of these studies have shown
that atrophy of the left frontal cortex, insula, and bilateral retro-
splenial cortices is associated with agitation,97 while disinhibition was
more closely associated with gray matter volume reductions of the
right subgenual cingulate gyrus AD of the right ventromedial pre-
frontal cortex.97 Conversely, aberrant motor behavior in AD appears
to be more closely associated with reduced gray matter volumes of
the right basal ganglia, right dorsal anterior cingulate, and left pre-
motor cortex.97 Another study found associations between the agi-
tation/aggression sub-scores of the NPI with right-sided posterior
atrophy,98 suggesting a predominantly right hemisphere influence on
this emotional control measure. Similar right-sided predominance of
hemispheric control of agitation was noted in studies using diffusion
tensor imaging (DTI) in which associations of higher severity of agi-
tation with fractional anisotropy reductions between the right fron-
totemporal and right parietal regions were observed.99 It is notable
that there is evidence that the severity of agitation may also be influ-
encedby thedegreeof executivedysfunctionor functional impairment,
and that agitation results froman interactionbetweenneuropathologi-
cal substrates of emotional dysregulation and environmental stressors
related to impaired task performance.
Impulsivity represents two distinct neuropsychiatric syndromes
with identifiable neuroanatomical correlates, which result in the
tendency to act prematurely in the absence of sufficient evidence
to support the action or without full consideration of its possible
adverse consequences.100 The first construct includes aberrant pro-
cessing of reward-processing and delay-discounting measures lead-
ing to risky decision making and “waiting” impulsivity. The second
construct reflects abnormal response-inhibition and cognitive dys-
regulation, including “stopping” or “reflection” impulsivity.100,101 The
pathological substrates of the first construct include neuronal loss
in subcortical structures, such as the striatal, thalamic, and subthala-
mic regions, which results in thalamocortical disinhibition, and sub-
sequently, impaired reward-response mechanisms.102,103 Neocortical
pathology, particularly in the prefrontal cortex, influences decision-
making, risk assessment, and action selection.104 Based on these
two distinct but interrelated pathways, impulsivity may be seen with
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prefrontal or subcortical lesions; degeneration of the limbic ventral
prefrontal cortex-striatal circuits is more likely to be associated with
risky decision-making and intolerance to delays,105 whereas impair-
ment in dorsal motor or cognitive circuits, such as the inferior frontal
gyrus or pre-supplementary motor area, is more likely to be associ-
atedwith inability to refrain fromor stop inappropriate actions.106 Dis-
ruption of monoaminergic systems, particularly serotonin and nora-
drenaline, has been implicated in impulsivity.107 Selective serotonin
reuptake inhibitors (SSRIs) and noradrenergic agents (eg, atomoxetine)
are commonly used to treat impulsivity due to neurodegenerative dis-
orders including AD.108–110 As the noradrenergic neurons of the locus
coeruleus have been shown to be affected in the earliest symptomatic
or pre-symptomatic stages of AD,111,112 impulsivity may be an impor-
tant indicator of early AD pathology in cognitively normal individuals.
6 THE NEUROIMAGING OF AGITATION
In 2015 we reviewed the literature on neuroimaging and agitation in
AD.113 It was proposed that agitation in ADwas associated with struc-
tural and functional deficits in a mix of brain regions associated with
core AD neuropathology (particularly hippocampus and posterior cin-
gulate cortex) as well as regions that may reflect other mechanisms
(amygdala, insula, frontal, and anterior cingulate cortices). Newer data
reinforce selected aspects of these hypotheses as reviewed below,
adding new functional and neurochemical hypotheses as well. Sev-
eral studies report an association of agitation in AD with volume loss
in frontal cortex,97,114 anterior cingulate cortex,114,115 posterior cin-
gulate cortex,97,114 insula,97,114,115 amygdala, and hippocampus.114
There are two published functional imaging studies of agitation in
AD. Hirono et al.90 found that agitation in AD with hypoperfusion
in left anterotemporal, right parietal, and bilateral dorsofrontal cor-
tex using single-photon emission computerized tomography. Weiss-
berger et al.116 reported that an agitation factor of the NPI was asso-
ciated with hypometabolism of right temporal, right frontal, and bilat-
eral cingulate cortex. Among the individual items in the agitation fac-
tor, agitation was associated with cingulate hypometabolism, irritabil-
ity with right frontal and insula hypometabolism, and both irritability
and agitationwith right temporal hypometabolism. There are two pub-
lished studies of brain connectivity in agitated AD patients, one struc-
tural and one functional. Tighe et al.117 reported that decreased func-
tional anisotropy (presumably reflecting decreased white matter tract
integrity) of the anterior cingulate was associatedwith agitation in AD.
Ogama et al. examined a group of females with mild to moderate AD
(n = 217) and amnestic MCI (aMCI) and found both whole brain white
matter hyperintensities and frontal lobe peri-ventricular hyperintensi-
ties to be associated with verbal aggressiveness.118 Balthazar et al.119
examined functional connectivity in 20 participants with mild to mod-
erate AD using resting state fMRI. They reported that a hyperactivity
factor score (including agitation) was associated with greater connec-
tivity in the anterior regions of the right salience network (SN) includ-
ing anterior cingulate and insula. Using fMRI to assess 169 participants
with either AD or aMCI, Serra et al. showed an association between
symptoms of agitation, irritability, and disinhibition with ventral
tegmental connectivity with the parahippocampal gyrus and cerebel-
lar vermis.120 There are two reports of neurochemical imaging of agi-
tation in AD. Using MR spectroscopy, (Tsai et al.121) reported that agi-
tation (measured with CMAI) correlated negatively with the NAA/Cr
ratio in the left posterior cingulate gyrus (r = −0.46; P = .02). Sultzer
et al.122 imaged 𝛼4𝛽2 nicotinic cholinergic receptor density using 2-
[18F] fluoro-3-(2(S)azetidinylmethoxy)pyridine (2FA) PET and found
that lower 2FA binding in anterior cingulate was strongly correlated
with the Neurobehavioral Rating Scale agitation/disinhibition score.
Although these neuroimaging results using multiple modalities are
somewhat disparate, they do point to some potential mechanisms. A
number of findings point to the association of amygdala and SN func-
tionwith agitation in AD. The amygdala (which is part of the SN) serves
to signal emotionally salient external stimuli and contributes to the
emotional awareness of an individual.123 In this context, it is notable
thatWright et al.124 using task-based fMRI of viewing faces with vary-
ing emotions, reported increased amygdala activation in AD patients
(compared to old and young controls) when viewing a sequence of
faces expressing emotion, and that the intensity of this signal corre-
lated with the severity of irritability and agitation. The anterior insula
has been implicated in awareness of one’s emotional state125; thus
the abovementioned evidence of insular dysfunction in agitated AD
patients suggests that they have deficits in monitoring their emo-
tional state. Another possible mechanism comes out of the literature
on brain mechanisms of anxiety disorders. As reviewed above, agita-
tion in AD is associated dysfunction in frontal cortex, anterior cin-
gulate cortex, orbitofrontal cortex, amygdala, and insula. These brain
areas overlap with circuits that underlie inflated estimations of threat
cost or probability, as well asmaladaptive control of responses.126 Agi-
tation in AD may involve miscalculation of the magnitude of poten-
tial threats, accompanied by increased threat, attention and vigi-
lance, and/or heightened reactivity to threat uncertainty. The patient
is hyper-attentive to threat and also overestimating the severity of
threat, resulting in emotional overreaction. In addition, agitation in AD
is associatedwith progression of coreADneuropathology in the poste-
rior cingulate cortex and hippocampus.
7 THE NEUROIMAGING OF IMPULSIVITY
Impulsivity is a multifaceted behavior that includes behavioral dis-
inhibition, risk-taking conduct, and impaired decision-making.127
Although impulsivity is commonly reported in AD,128 there have been
few neuroimaging studies that specifically evaluate the neuroanatom-
ical correlates of impulsivity in AD. This may be due to the NPI63 being
commonly used in most AD studies to measure NPS and impulsivity
is not included in the sub-components of NPI, as it is framed as social
disinhibition in this scale. However, very recently, Gill et al.129 utilized
traditional statistics and machine learning models to explore DTI
and volumetric parameters in 203 participants from ADNI including
those with normal cognition, MCI and AD, and MBI impulse dyscon-
trol derived from the NPI-Q using a published algorithm.57 Linear
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mixed-effects models identified impulse dyscontrol to be associated
with increased mean axial and radial diffusivity in the cingulum, fornix,
inferior/superior fronto-occipital fasciculus, and gray matter atrophy
in parahippocampal gyrus and hippocampus, while machine learning
selected nine features to predict presence of MBI ID. Although the
cingulum and fornix were features consistent with those identified
by conventional statistics, machine learning also identified the supe-
rior cerebellar peduncle, corpus callosum, supramarginal gyrus, and
superior frontal regions, which may be targets for further exploration.
On the other hand, there have been various neuroimaging studies of
impulsivity in PD, as ICD is a common neuropsychiatric complication of
PD. Therefore, we will review the neuroimaging studies of impulsivity
in PD to elucidate the structural, functional and metabolic correlates
of impulsivity.
There have been inconsistent findings regarding cortical thickness
in PD patients with impulsivity. Significant cortical thinning in the
fronto-striatal circuits, specifically in the right superior orbitofrontal,
left rostral middle frontal, bilateral caudal middle frontal region, and
corpus callosum; and volume reduction in the right accumbens and
concomitant increased volume in the left amygdala have been reported
in PDpatientswith ICD.130 Furthermore, a recent study shows that PD
patientswith impulsive-compulsive behaviors (ICBs) have cortical thin-
ning in the left precentral and superior frontal regions.131 However,
another study reports an increase in cortical thickness in the anterior
cingulate and orbitofrontal cortices in PD patents with ICD,132 while
one other study demonstrates no difference in gray matter volume
between PD patients with and without ICD.133 In the same study, an
increased connectivity within the salience and default-mode networks
and a decreased connectivity within the central executive network
is found to be associated with ICD in PD.133 Another resting-state
functional study found that PD patients with ICB compared to those
without ICB, are associated with altered connectivity between the
left anterior putamen, left inferior temporal gyrus, and left anterior
cingulate gyrus,134 while in a recent study, the severity and duration
of PD-ICB in PD is shown to modulate the functional connectivity
between sensorimotor, visual, and cognitive networks.131 A FDG-PET
study further shows that PD patients with higher impulsivity scores
have higher metabolism in the orbitofrontal cortex, anterior cingulate
cortex, and right insula.135
Current evidence has consistently shown that impulsivity is asso-
ciated with brain dysfunction involving the frontal-striatal and meso-
limbic regions. The dorsolateral and medial prefrontal cortices, includ-
ing the orbitofrontal cortex, anterior cingulate cortex, and the ventral
striatum, have been reported to play an important role in impulsive
behaviors due to abnormal emotions, decision-making, and impulse
control,136 whereas the amygdala plays a key role in associating sen-
sory cues with their motivational and emotional significance.
8 BIOMARKERS OF NPS
The pathogenesis of NPS in neurodegenerative disorders is not
entirely clear, although several different hypotheses have been
proposed. To increase our knowledge of the different proposed mech-
anisms associated with the presence of NPS different biomarkers
such as blood, plasma, and cerebrospinal fluid (CSF) might be studied
through analytic genomics, proteomics, and lipidomics techniques.
Potential markers include: AD markers (tau, phosphorylated tau
(P-tau), and amyloid beta(A𝛽)1-42, 38, and 40); cholinergic markers
(acetylcholinesterase (AcHE), butyrylcholinesterase (BChE)); seroton-
ergic markers (5-hydroxytryptamine (5-HT), 5-hydroxyindoleacetic
acid (5-HIAA)); noradrenergic (noradrenaline (NA), 3-methoxy-
4-hydroxyphenylglycol (MHPG)); dopaminergic (dopamine (DA),
3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA),
3-methoxytyramine (3-MT)); neuroinflammation (cytokines, glycopro-
tein YKL-40); synaptic damage markers (neurogranin); axonal damage
markers (neurofilament); and neurotrophic factors (brain-derived neu-
rotrophic factor (BDNF), vascular endothelial growth factor (VEGF),
S100 calcium-binding protein B (S100B)).
Ruthirakuhan et al. recently conducted a systematic review focused
on the biomarkers of agitation and aggression in AD. They found that
the associations between apolipoprotein E(APOE) 𝜀4 carrier status and
agitation and aggression in AD have been largely inconsistent.137 One
retrospective study found that the hazard of developing AD for APOE
𝜀4 carrierswas significantly higher for thosewith baseline agitation.138
Another study showed a higher frequency of APOE 𝜀4 carrier status
in patients with AD who have agitation.139 One genetic study found
no associations of APOE 𝜀4 carrier status with agitation, but demon-
strated mild associations of suppressed frontally mediated behaviors
in AD with genotypes that lead to boosted angiotensin-converting
enzyme levels and activity, or with lipid metabolism genotypes related
to improved myelin biosynthesis in the brain.140 Another genetic
study found associations of the T allele of the 3′ untranslated region
of prion-like protein gene (PRND) polymorphism with an increased
cumulative behavioral load and an elevated risk for delusions, anxi-
ety, agitation, apathy and irritability for patients with AD, but not for
patients with MCI, and for no patient group regarding APOE 𝜀4 carrier
status.141
The strongest evidence for the role of agitation and impulsivity in
mid and late life over further development or progression of dementia
has come from longitudinal studies.Whereasmost prospective cohorts
have employed essentially clinical measures of patient evaluation
in longitudinal clinical and epidemiological studies,5,14,20,38,128,142–153
some studies have correlated neuroanatomical parameters114,154 and
biomarkers of amyloidogenesis155 withNPS. Bloniecki et al. found that
in a cohort of subjects with AD and NPS agitation measured with the
Cohen-MansfieldAgitation Inventory (CMAI) correlatedwith total-tau
(r = 0.36, P = .04) and phosphorylated-tau r = 0.35, P = .05) in AD
patients, indicating that tau-mediated pathology including neurofibril-
lary tangles and the disease intensity might be associated with agita-
tion in AD.156,157 In their systematic review of CSF correlates of NPS
in AD and aMCI, Showraki et al. found that all studies that met inclu-
sion criteria and examined the relationship of Core AD CSF biomark-
ers (LowA𝛽42, elevated tau, etc.) with the agitation/aggression domain
of NPS, demonstrated a significant relationship between Core AD CSF
biomarkers and the agitation/aggression domain.158
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The serotonin system may play a role in the development of NPS
in MCI. In 2017, Smith et al., using the radiotracer [11C]-3-amino-
4-(2-dimethylaminomethyl-phenylsulfanyl)-enzonitrile ([11C]-DASB),
showed that as compared to normal controls, participants with MCI
had fewer serotonin transporters in the cortical and limbic regions of
the brain. MCI participants in this study had NPS in the mild range,
which was significantly higher than in normal controls.159 Measured
serotonin transporters act as a more specific marker of serotonin ter-
minals and serotonin projection integrity than serotonin receptors 1A
or 2A.160 Yet, it remains unclear how these decreases in serotonin
transporters inMCI participants relate to the emergence of NPS.
The relationshipbetweencytokines, neuroinflammation, andNPS in
AD is complex and not entirely elucidated at this point. Holmgren et al.
analyzed the relationships between NPS in dementia and CSF levels
of cytokines including: interleukin(IL)-6, tumor necrosis factor (TNF)-
𝛼, IL-10, and cytokine receptor soluble form IL-1RII. The 95 subjects
analyzed in this study included patients with MCI, AD, VasD, and AD
and vascular mixed dementia. All subjects scored ≥10 on the NPI total
score.161 Levels of the anti-inflammatory cytokine, IL-10, correlated
inversely with the NPI total score (P= .004), the NPI sub-scores of agi-
tation (P= .009), and night time behaviors (P= .01) and trended toward
an inverse correlationwith depression (P= .09). TNF-𝛼 CSF levelswere
undetectable and IL-6 CSF levels did not show any correlations with
NPS.161
Using a sickness behavior paradigm, Holmes et al. examined the
relationships between NPS and serum levels of pro-inflammatory
cytokines TNF-𝛼, IL-6, and C-reactive protein (CRP) in a cohort of 275
subjects with either possible or probable AD over a 6-month time
span.162 Sickness behaviors refer to a set of behavioral symptoms,
such as depression, anxiety, and apathy, that occur during the course
of systematic inflammation and which may serve adaptive purposes.
A total of 222 subjects had complete clinical and serum inflammatory
marker data at 6-month follow-up. Subjects with low TNF-𝛼 serum lev-
els throughout the 6 months had lower NPI total scores as compared
to subjects with high TNF-𝛼 serum levels. The high TNF-𝛼 serum level
grouphad significantlyhigher frequenciesof agitation (P= .02), depres-
sion/dysphoria (P= .008), and anxiety (P= .01). There were no statisti-
cally significant differences in agitationbetween thehigh and lowquar-
tiles for IL-6 and the high and low quartiles for CRP, although the high
versus low IL-6 quartiles did have more frequent hallucinations (P =
.015) and apathy (P= 003).162
A study of 16 AD patients and 16 normal controls conducted
in Japan examined the relationships between agitation, circadian
rhythms of behavior, and serum levels of cortisol, IL-1𝛽 and Natural
Killer Cell Activity (NKCA) over 1 year. The 16 subjects were catego-
rized into stages of stable, pre-agitation, and agitation. When compar-
ingAD subjects in the stable stage toAD subjects in the agitation stage,
there was a statistically significant increase in serum cortisol and IL-1𝛽
and decrease in NKCA.163
A recent clinical trial with nabilone as a treatment for agitation in
AD examined biomarker changes associated with treatment response
in 38 subjects. The double-blinded, 14-week-long, cross- over, random-
ized, placebo-controlled trial included 6 weeks in the drug phase and 6
weeks in the placebo phase, with a 1-week washout period. Even after
adjusting for cognition, serum levels of the pro-inflammatory cytokine
TNF-𝛼 correlated with agitation severity (P= .04). During the nabilone
treatment phase, a lower baseline TNF-𝛼 serum level demonstrated an
association with decreases in agitation severity. Decreases in TNF-𝛼
were also associated with decreases in agitation severity.164
In total these studies suggest that several pro-inflammatory
cytokines levels directly correlate with agitation frequency161,162 and
severity,163,164 while anti-inflammatory cytokine levels inversely cor-
relate with agitation,161 and agitation treatment response to nabilone
correlateswithdecreases inTNF-𝛼164 (SeeFigure2). It shouldbenoted
that most of the biomarker work that has been done in NPS focuses
on people with dementia or at high risk of converting to dementia
within 5 years. Understanding earlier cytokine and other biomarker
changes associated with agitation and impulsivity remains an impor-
tant research question that has not yet been fully answered.
9 COURSE AND PROGNOSIS
There has been growing evidence in the literature that agitation and
impulsivity in mid and late life may be risk markers for progression to
dementia in later years. Most longitudinal studies discuss the progres-
sion of MCI to AD or to another dementia without discussion of eti-
ology. For the most part, studies regarding agitation and impulsivity
in other neurodegenerative diseases (such as FTD or DLB) have been
either cross-sectional studiesor studies focusedonpatientpopulations
with NPS who already meet criteria for major neurocognitive disorder
or dementia.
Most studieswere conducted before the provisional consensus clin-
ical and research definition of agitation in cognitive disorders elabo-
rated by members of the IPA35 or the ISTAART research diagnostic
criteria for MBI,26 thus compromising generalizability. Overall, they
do notmentionwhether agitation impaired interpersonal relationships
or the ability to participate in activities of daily living. The instru-
ments that were employed for evaluation of agitation and impulsivity
were highly variable across studies, although most of them included
assessment of the agitation/aggressiondomain of theNPI (as discussed
previously).63
A few cross-sectional studies were able tomeasure the progression
of agitation by dementia stage in late-onset AD,140,165,166 early onset
AD,167,168 or group comparisons of MCI versus dementia65,169,170
or MCI versus older cognitively unimpaired people.39 One cross-
sectional study also showed that intensity of agitation correlates
with CSF biomarkers of neurodegeneration in patients with AD, but
not in patients with VasD or mixed dementia157; the same may be
true for patients with MCI.171 The severity of dementia is associated
with increased intensity of aggressive behavior both in nursing home
patients172 and in community-dwelling patients.173
One cross-sectional study showed that agitation was non-
significantly less frequent and less intense in PD dementia than in
late-onset AD or in DLB.174Regarding primary progressive aphasia,
one retrospective study showed that patients with semantic primary
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progressive aphasia developed more frequent and intense agitation
than patients with non-fluent primary progressive aphasia, unrelated
to length of the neurodegenerative disease.175
Most of the data on the effects of agitation, aggression, and impul-
sivity have come from longitudinal studies of patients with diagnosed
AD. There is consistent evidence that the presence of one or more
of these symptoms, as well as delusions and hallucinations as psy-
chotic features, is associated with an increased likelihood of greater
cognitive decline, admission to nursing homes, andmortality.148,150,153
There is initial evidence that the presence ofmild behavioral symptoms
that may not reach the threshold of agitation/aggression or impulsiv-
ity is associated with the development of dementia in older adults.81 It
remains unclear if thepresenceof agitationor impulsivity in cognitively
intact older adults is also aprecursor todementia, and there is evidence
that these symptoms rarely occur when patients first present with
memory complaints for a diagnostic evaluation.176 A recent prospec-
tive study of 96 subjects with MCI conducted in France for 4 years
demonstrated the presence of agitation/aggression as a risk factor for
conversion to dementia (hazard ratio [HR] 3.9 confidence interval [CI]
1.9-8.2).177
It is expected that long-term studies starting in mid-life, prefer-
ably incorporating neuroimaging and biofluid-based biomarkers, might
bring further evidence on the role of agitation and impulsivity as risk
markers for neurocognitive disorders in later years.
10 TREATMENT OF AGITATION AND
IMPULSIVITY IN PRE-DEMENTIA
SYNDROMES
Of the publications included in this review, we did not find any studies
specifically addressing the treatment of agitation and impulsivity
in patients with cognitive impairment without dementia and/or
pre-dementia syndromes that do not include cognitive impairment.
Although, there is a significant body of evidence regarding treatment
of agitation and impulsivity in patients with AD, FTD, DLB, and PD,
one cannot extrapolate and assume that these treatments will be
effective in the cognitive impairment no dementia, or pre-dementia
syndromes.We review current treatments of agitation and impulsivity
in the dementia population to inform potential future treatments
in pre-dementia syndromes. This is not an endorsement or recom-
mendation of applying these treatments to those with pre-dementia
syndromes. Clinical trials need to be conducted to test and prove that
behavioral and pharmacologic treatments in pre-dementia populations
can effectively improve agitation and impulse dyscontrol.
In patients with AD, behavioral interventions are recommended
as first-line interventions and are supported by high quality
evidence.178–181 Specifically the interventions focusing on improv-
ing communications, individualized care, interventions to support
caregivers, music therapy, and dementia care mapping have shown
efficacy in this population.180 Among medications, the antipsychotic
medications have the most direct evidence for treatment of agitation
and aggression in dementia with multiple RCTs supporting their
efficacy.182–189 However these medications are associated with
several adverse effects such as extrapyramidal symptoms, metabolic
syndrome, stroke, falls, and an increased risk of death.183,190 Nev-
ertheless these medications are used widely for this indication,
particularly in patients with severe agitation and aggression.191–194
There is also evidence for use of citalopram for treating agitation
in patients with AD.110,195–197 A recent large multicenter RCT has
shown efficacy of citalopram in treating agitation in patients with AD
and mild to moderate degree of cognitive impairment, but concerns
were raised about QTc interval prolongation and cognitive decline
with drug versus placebo.110,198 Further analysis of data from this trial
revealed that the S-citalopram enantiomer was responsible for most
of the benefits, whereas the R-citalopram enantiomer was responsible
for most of the adverse effects such as cognitive decline and QT
interval prolongation.199 Other agents that have shown efficacy in this
population are anticonvulsants with carbamazepine having RCT level
evidence.200,201 Valproic acid showed some favorable results in open
label trials but these findings were not replicated in RCTs where there
was a clear lack of benefit and a high rate of adverse events, and thus
it is not recommended for use in this population.202 In addition, when
used to treat people with dementia, retrospective evidence suggests
that valproic acid has an increased mortality rate, comparable to some
antipsychotics and possibly higher than the atypical antipsychotic
quetiapine.203 Studies in patients with FTD have shown good quality
evidence for trazodone followed by SSRIs for treatment of agitation
and impulsivity, and thesemedications are favored over antipsychotics
in this population.204–207 Antipsychotics are still recommended for
more severe cases with agitation and aggression that pose a safety
risk.204 Cholinesterase inhibitors have been shown toworsen agitation
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TABLE 1 Representative studies on the course of agitation and impulsivity as risk markers for neurocognitive disorders




Prospective 270 Pittsburgh compound B PETmeasures of
cortical aggregate A𝛽 , depressionmeasures,
and depressive symptom clusters in
cognitively healthy older adults.
Higher A𝛽 burdenwas associatedwith increasing
anxious-depressive symptoms over time in
cognitively healthy older adults, supporting the
hypothesis that emerging neuropsychiatric






201 Cerebrovascular metabolism genotypes, NPS in
late-onset AD
Agitation frequency and severity increasedwith
increasing severity of AD,Mild AD (50.0%), Mod AD
(63.0%), and Sev AD (74.2%)
Burke et al.,
2016138
Retrospective 11,453 Survival analyses betweenNPS, APOE 𝜀4 carrier
status, and progression to AD in cognitively
healthy adults
Hazard of AD development for APOE 𝜀4 carriers was
approx 13X higher for patients with delusions and
11X higher for those with apathy and disinhibition.
Also greater rates for those with hallucinations,




Prospective 540 Clusters of NPS in patients with incidentMCI
and risk of conversion to dementia
Most patients who progressed to dementia had aMCI
at baseline, whereas patients with the severe NPS
cluster (agitation, anxiety, apathy, night-time
behaviors, disinhibition) had the highest hazard of





Retrospective 80 Prevalence of agitation in semantic PPA and
non-fluent PPA, and clinical variables
Patients with semantic PPA developedmore frequent
and intense agitation, with greater need for
anti-psychotics than patients with non-fluent PPA.






78 Differentiation of DLB from PDD byway of
NPS, as well as behavioral contrasts between
patients with DLB syndromes paired with
APOE 𝜀3/𝜀3 carriers with LOAD
Agitation prevalence varied by group: PDD (28.6%),




Prospective 1,449 Development of a risk score for incidentMCI,
including NPS asmeasured by the NPI.




Prospective 335 Examination of the relationship between
clinically significant NPS inmild AD and
progression to severe dementia or death
Almost 20% of all patients with incident AD developed
severe dementia, withmore rapid progression
associatedwith agitation and psychosis, features
that also predicted earlier death
Pink et al.,
201514
Prospective 332 A population-based study that assessed the
interaction between APOE 𝜀4 carrier status,
NPS, and the risk of incident dementia among
subjects withMCI
Hazard ratios for conversion fromMCI to dementia
were significant regarding baseline agitation (1.97),
night-time behaviors (1.68), depression (1.63), and





261 Characterization of NPS in people without
dementia who carried autosomal dominant
ADmutations with non-carriers
Depression, apathy, disinhibition, irritability, sleep
changes and agitation weremore common and the
degree of self-rated depressionmore severe inmildly
symptomatic mutation carriers relative to
non-carriers. Lower rates of depressive symptoms







1,072 Assessment of frequency of NPS in relation to
dementia severity, as well as specific clusters
of NPS
Agitationwas themost commonNPS, present in 37% of
all patients, whereas decreased initiative was related







92 Changes in agitation in the placebo arm of the
CitAD study
Patients with ADwho received placebo and a
psychosocial intervention over 9 weeks had
improvements in agitation scores, cognition and
function, possibly due to regression to themean,
response to the intervention, natural course of
symptoms, or nonspecific benefits of participation in
a trial
(Continues)
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92 Investigated the relationship between dementia
severity andNPS in early onset AD
Agitation, apathy, disinhibition, irritability, and aberrant
motor behavior worsenedwith dementia severity in




Prospective 517 Characterization of the relationships between
agitation and cognition or dependence in
patients with probable Alzheimer’s disease
Rates of increase in agitation separately correlated







95 Examination of the association between
agitation and cerebrospinal fluid amyloid beta
1-42, total tau and phospho-tau in patients
with AD, vascular dementia, or mixed
dementia who had behavioral disturbances
Intensity of agitation correlatedwith cerebrospinal
fluid total tau and phospho-tau in patients with AD,







217 Evaluation of the prevalence of agitation
according to the stage of AD, as well as of
correlations of pharmacological treatment
with stage-specific NPS
Agitationwasmore frequent andmore severe with
increasing severity of AD, affecting 51.8% ofmildly
impaired patients, 65.4% of moderately impaired
patients, and 70.0% of severely impaired patients,
whereas cholinesterase inhibitors and
anti-psychotics (but not anti-epileptic drugs) were
associatedwithmore agitation for moderately




Prospective 1,587 Estimation of the risk of incidentMCI in
cognitively unimpaired older people
according to baseline NPS
Baseline agitation, apathy, anxiety, irritability and
depression increased the risk for laterMCI, while




Prospective 931 Investigation of the course of NPS in nursing
home patients with dementia over 53months
Agitation, irritability, disinhibition and apathy were the
most prevalent and persistent symptoms, and







268 Investigation of associations of CSF
concentrations of amyloid beta 1-42 and total
tauwith NPS in patients withMCI
Anxiety was associatedwith abnormal CSF
concentrations of A𝛽 1-42 and total tau, while
agitation and irritability were associatedwith
abnormal CSF concentrations of A𝛽 1-42 only.
Trzepacz et al.,
201366
Prospective 462 Characterization of neuroimaging parameters
associatedwith agitation in patients with
probable AD, stable patients withMCI, and
patients withMCI converting to AD
Agitationworsened in patients with probable AD and in
patients withMCI converting to AD, whereas
severity of agitation was associatedwith greater
atrophy of the anterior salience network (frontal,
insular, amygdala, cingulate, and hippocampal








780 Characterization of behavior inMCI, AD, and
cognitively healthy adults
The prevalence and severity of agitation inMCI was
intermediate between normal aging and AD
Bettney et al.,
2012143
Prospective 84 Investigation of the stability of neuropsychiatric
sub-syndromes with progression of vascular
dementia and AD
Themost stable group of symptoms included delusions,
hallucinations, irritability and agitation, with
evidence of some stability particularly during the
later stages of dementia
Bidzan et al.,
2012128
Prospective 31 Assessment of the relationship between
agitation and impulsivity and cognitive
function in nursing home patients with AD
Worse cognitive function was associated with greater
intensity of agitation and impulsivity, but the




Prospective 873 Evaluation of cognitive decline in 2 years
according to NPS in community-dwelling
older people with no diagnosis of dementia
Baseline agitation and apathy were associatedwith
diagnosis ofMCI, whereas depression, agitation,
anxiety and apathy were associated with impairment
in at least one cognitive domain, but only anxiety and
agitation were significantly associatedwith cognitive
decline
(Continues)
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147 Assessment of associations between APOE,
CYP46, PRNP, and PRND polymorphisms and
the neuropsychiatric profile of patients with
MCI and AD
The T allele of the 3′ untranslated region of PRND
polymorphismwas associatedwith increased risks
for delusions, anxiety, agitation, apathy and





304 Investigation of the relationship between
dementia severity, age, gender, prescription
of psychotropics, and agitation in nursing
home patients with dementia
Dementia severity predicted higher risk for agitation
and depression, whereas the severity of depression
was associatedwith physically and verbally
aggressive behaviors, indicating that, in severe





Prospective 812 Investigation of the relationship between
neuropsychiatric symptoms and global
functional impairment at baseline and over 3
years in cognitively healthy older people,
patients withMCI, and patients withmild AD
Increased baseline hallucinations, anxiety and apathy
(but not agitation) were associated with greater
global functional impairment at baseline, whereas
the presence of hallucinations and apathy at baseline
(but not agitation) was associatedwith greater global





Prospective 86 Determination of baseline clinical
characteristics, including anatomical subtype,
that could predict functional decline in
behavioral variant frontotemporal dementia
Faster rates of functional decline were observed in the
frontal dominant and frontotemporal subtypes of
behavioral variant frontotemporal dementia,
whereas participants with less agitation,
disinhibition, and night-time behaviors at





1,015 Investigation of the relationship between
specific NPS and severity of AD
Agitation had an increased occurrencewith increasing
severity of untreated AD, reaching clinical






1,909 Estimation of the prevalence of NPS inMCI and
cognitively unimpaired older people in a
population-based study
Themost distinguishing features between the groups,
all of themmore frequent in patients withMCI, were
apathy, agitation, anxiety, irritability and depression,
whereas apathy, agitation and irritability weremore




Prospective 497 Investigation of the presence of disruptive
behavior (wandering, agitation, aggression,
sundowning) and its predictive value for
decline in cognition decline in function,
institutionalization andmortality for patients
withmild AD
Sundowningwas associatedwith faster cognitive
decline, wandering with faster functional decline and
institutionalization, and agitation with faster
cognitive and functional decline, whereas disruptive





400 Association of agitation with APOE haplotypes
inmoderate to severe AD
Higher frequency of APOE 𝜀4 carriers among patients
with agitation, also notedwhen APOE 𝜀4 carriers





454 Comparisons of prevalent NPS in
community-dwelling older people with
dementia orMCI
Compared to patients with dementia, those withMCI
had lower prevalence of any NPS (psychosis,




Prospective 144 Assessment of the impact of cognition on
functional abilities andNPS over 3 years to
determinewho had functional decline and
who developed AD
Particular types of personality change, such as
agitation and passivity, but not depressive
symptoms, were related to functional decline
Lopez et al.,
1999148
Prospective 179 Examination of whether use of psychiatric
medication and the presence of abnormal
behaviors affect progression of AD
Use of anti-psychotics was associated with functional
decline. Use of hypnotics was associatedwith death.
Psychosis and agitation predicted functional decline





Prospective 235 Development and persistence of
psychopathologic symptoms in patients with
AD
Agitationwas prevalent at least once in 62.2% of
patients and persisted inmost of them along 3 years
of follow-up, with almost 50% increase in prevalence
throughout the study
(Continues)
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References Study design n Endpoints Findings
Levy et al.,
1996147
Prospective 181 Recurrence of agitation in 1 year in patients
with AD
Recurrence rates of agitation at one year reached 93%
andwere associated withmore rapid functional
decline. Recurrences were greater in patients who





213 Assessment of predictors and consequences of
aggressive behavior by community-dwelling
patients with dementia
Aggression was reported in 57.2% of patients,
predicted by greater frequency of behavior and
memory problems, premorbid aggression, and amore
troubled premorbid social relationship between
patient and caregiver, whereas patient aggression
predicted the decision to discontinue home care
and impulsivity in FTD and are thus avoided in this population.207 In
contrast, in patients with DLB, cholinesterase inhibitors may improve
NPS, including agitation and impulsivity, and may be used as first-line
agents.208 Antipsychotic medication use is relatively contraindi-
cated in DLB as it can precipitate severe extrapyramidal symptoms;
however, there is evidence to support the use of clozapine and que-
tiapine (weaker evidence) in small doses.209,210 In patients with PD,
impulsivity is associated with dopamine agonists in a significant
proportion of cases and may respond to dopamine agonist dose
reduction.211,212 Empirical use of other agents such as cholinesterase
inhibitors, antipsychotics, antidepressants, and mood stabilizer med-
ications is also reported.212 The use of deep brain stimulation for
impulsivity related to PD is controversial.213 Some studies provide
support for the use of electroconvulsive therapy for NPS of dementia,
particularly in patients with treatment refractory illness but it is an
invasive procedure associated with several risks including cognitive
adverse effects.214,215 There is no evidence for or against other non-
invasive brain stimulation interventions such as transcranial magnetic
stimulation or transcranial electrical stimulation for treatment of
agitation or impulsivity in cognitive disorders.
Ongoing clinical trials may also help clarify which pharmacother-
apeutic treatments may be suitable for pre-dementia populations.
These include studies of: (1) escitalopram (NCT03108846)216; (2)
mirtazapine (NCT03031184)217; (3) cannabinoids (NCT04075435,
NCT02792257)218,219; (4) prazosin (NCT03710642)220; (5) brex-
piprazole (NCT03548584)221; (6) dextromethorphan-quinidine
(NCT03393520)222; and (7) lithium (NCT02129348),223 among
others.
11 CONCLUSION
This review highlights a gap in the literature regarding agitation and
impulsivity (part of the MBI domain of impulse dyscontrol) and the
role they play as risk factors for incident cognitive decline and demen-
tia. Numerous studies show that in general, NPS predict progression
from normal cognition and MCI to dementia. A smaller body of evi-
dence suggests that this is true for agitation and impulsivity aswell. Yet,
there are significant limitations with the current literature base. First,
nearly all scales used to study agitation and impulsivity in pre-dementia
populations were designed and validated for populations with demen-
tia or major neurocognitive disorder, rather than for patients with
normal cognition or MCI. Ongoing validation studies for the MBI-C
seek to address this first gap. A second problem with the literature is
that most epidemiologic, biomarker, longitudinal, and treatment stud-
ies took place prior to creation of the IPA agitation in cognitive disor-
ders criteria and the ISTAART MBI research diagnostic criteria. Vari-
ation in nomenclature and definitions complicate interpretations of
study results. In addition, unlike in agitation, there is no current inter-
national consensus definition or criteria for impulsivity, making the
symptommore difficult to effectively study and treat. This contributes
to impulsivity in normal cognition and MCI populations being under-
studied as an NPS as compared to agitation. Next, more work needs
to be done to describe the biomarkers associated with the impulse
dyscontrol subdomain of MBI. Furthermore, prevalence of agitation
and impulsivity varywidely according to study. Thismay be a reflection
of pre-dementia syndromes with different underlying etiologies being
grouped together. Finally„ treatment studies are largely extrapolations
from studies that focus on mixed populations of MCI and dementia, or
dementia alone.
From review of the existing evidence in similar disorders we make
the following recommendations around treatment of agitation and
impulsivity in pre-dementia syndromes. First, the etiology of agita-
tion and impulsivity and the underlying condition leading to these
symptoms should be determined with appropriate clinical workup.
This is important, as the treatment is likely to vary depending on
underlying etiology, which could range from a medical cause such
as delirium or TBI, pre-existing psychiatric condition, substance use,
and late-onset primary psychiatric disorder, to early manifestations
of a neurodegenerative disorder. Second, iatrogenic causes such as
dopamine agonist–induced agitation and impulsivity and antipsychotic
induced akathisia should be addressed. Third, we are unable to recom-
mend non-pharmacologic or pharmacologic interventions at this time,
because the studies have not been done and there is not sufficient
evidence to make such a recommendation at this time. Fourth, future
studies should examine the risks and benefits of non-pharmacologic
and pharmacologic (antidepressant, antipsychotic, mood stabilizer,
and others) interventions that have been found to be effective in
treatment of agitation and impulsivity in dementia. It needs to be
determined if treatment of later-life emergent and sustained NPS in
16 of 22 BATEMAN ET AL.
pre-dementia populations will change the disease course and delay
or prevent incident cognitive decline and dementia. Similarly, studies
are also required using dementia disease-modifying drugs in MBI NPS
to determine their role in disease course modification. Finally, efforts
should be made to explore the role of non-invasive brain stimulation
to develop novel biomarkers and targeted treatment interventions for
patients with agitation and impulsivity in pre-dementia syndromes,
as an alternative to pharmacological interventions, which are the
mainstay of current treatment.
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